Screener / SEC EDGAR /CIK 0000886163 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

Ligand Pharmaceuticals Inc LGND

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers LGND said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Diluted EPS (company-defined)
Fiscal 2026
Given $8.00 to $9.00 release Feb 26, 2026
Raised $8.50 to $9.50 release May 7, 2026
Raised $9.50 to $9.75 release Oct 29, 2026
– No standard number
The company's words
Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share 1 of $8.00-$9.00 release Feb 26, 2026
The Company continues to expect adjusted earnings per diluted share 1 of approximately $8.50 to $9.50 and full-year 2026 royalty revenue to be in the range of $225 million to $250 million. release May 7, 2026
Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance release Oct 29, 2026
Revenue
Fiscal 2026
Given $200.00M to $225.00M release Feb 26, 2026
Raised $225.00M to $250.00M release May 7, 2026
Kept $225.00M to $250.00M release Aug 6, 2026
– Not reported yet
The company's words
Ligand also expects 2026 royalty revenue to be in the range of $200 million to $225 million, revenue from sales of Captisol to be in the range of $35 million to $40 million and contract revenue to be in the range of $10 million to $20 million, resulting in total revenue of $245 million to $285 million. release Feb 26, 2026
The Company continues to expect adjusted earnings per diluted share 1 of approximately $8.50 to $9.50 and full-year 2026 royalty revenue to be in the range of $225 million to $250 million. release May 7, 2026
Full-year 2026 royalty revenue to be in the range of $225 million to $250 million release Aug 6, 2026
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $6.00 to $6.25 release Feb 27, 2025
Kept $6.00 to $6.25 release May 8, 2025
Raised $7.40 to $7.65 release Nov 6, 2025
– No standard number
The company's words
Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6.00-$6.25 release Feb 27, 2025
Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25 1 release May 8, 2025
Ligand is increasing its 2025 full year financial guidance. … The Company now expects total core revenue of $225 million to $235 million (previously $200 million to $225 million) and core adjusted earnings per diluted share 1 of $7.40 to $7.65 (previously $6.70 to $7.00). release Nov 6, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $180.00M to $200.00M release Feb 27, 2025
Kept $180.00M to $200.00M release May 8, 2025
Raised $200.00M to $225.00M release Aug 7, 2025
Raised $225.00M to $235.00M release Nov 6, 2025
$268.09M
10-K filed 2026-02-27
Above the range
The company's words
2025 Financial Guidance … These revenue components result in a total revenue forecast of $180 million to $200 million. release Feb 27, 2025
Ligand is reaffirming its 2025 full year financial guidance. … These revenue components result in a total revenue forecast of $180 million to $200 million. release May 8, 2025
2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share 1 increased to $6.70 - $7.00 (previously $6.00 - $6.25) release Aug 7, 2025
2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings per diluted share 1 increased to $7.40 - $7.65 (previously $6.70 - $7.00) release Nov 6, 2025
Revenue (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $225.00M to $235.00M release Nov 6, 2025
– No standard number
The company's words
Ligand is increasing its 2025 full year financial guidance. … The Company now expects total core revenue of $225 million to $235 million (previously $200 million to $225 million) and core adjusted earnings per diluted share 1 of $7.40 to $7.65 (previously $6.70 to $7.00). release Nov 6, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $130.00M to $142.00M release Feb 27, 2024
Kept $130.00M to $142.00M release May 7, 2024
Raised $140.00M to $157.00M release Aug 6, 2024
Raised $160.00M to $165.00M release Nov 7, 2024
$167.13M
10-K filed 2025-02-28
Above the range
The company's words
2024 Financial Guidance … These revenue components result in total revenue forecast of $130 million to $142 million. release Feb 27, 2024
Ligand is reaffirming its 2024 financial guidance. … These revenue components result in total revenue forecast of $130 million to $142 million. release May 7, 2024
Ligand is reaffirming its 2024 financial guidance given on July 8, 2024. … These revenue components result in total revenue forecast of $140 million to $157 million. release Aug 6, 2024
2024 full year revenue guidance increased to $160 million - $165 million (previously$140 million - $157 million) and core adjusted earnings per diluted share 1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) release Nov 7, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-27), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.